DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $31.76 billion. The enterprise value is $31.65 billion.
| Market Cap | 31.76B |
| Enterprise Value | 31.65B |
Important Dates
The next estimated earnings date is Thursday, July 24, 2025, after market close.
| Earnings Date | Jul 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 392.11 million shares outstanding. The number of shares has decreased by -3.45% in one year.
| Current Share Class | 392.11M |
| Shares Outstanding | 392.11M |
| Shares Change (YoY) | -3.45% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 94.39% |
| Float | 389.38M |
Valuation Ratios
The trailing PE ratio is 60.81 and the forward PE ratio is 36.93. DexCom's PEG ratio is 1.62.
| PE Ratio | 60.81 |
| Forward PE | 36.93 |
| PS Ratio | 7.69 |
| Forward PS | 6.51 |
| PB Ratio | 14.01 |
| P/TBV Ratio | 14.79 |
| P/FCF Ratio | 55.22 |
| P/OCF Ratio | 32.95 |
| PEG Ratio | 1.62 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.89, with an EV/FCF ratio of 55.02.
| EV / Earnings | 59.13 |
| EV / Sales | 7.63 |
| EV / EBITDA | 36.89 |
| EV / EBIT | 50.03 |
| EV / FCF | 55.02 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.14.
| Current Ratio | 1.50 |
| Quick Ratio | 1.27 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 2.89 |
| Debt / FCF | 4.49 |
| Interest Coverage | 33.12 |
Financial Efficiency
Return on equity (ROE) is 23.72% and return on invested capital (ROIC) is 8.16%.
| Return on Equity (ROE) | 23.72% |
| Return on Assets (ROA) | 5.98% |
| Return on Invested Capital (ROIC) | 8.16% |
| Return on Capital Employed (ROCE) | 17.03% |
| Revenue Per Employee | $402,718 |
| Profits Per Employee | $51,961 |
| Employee Count | 10,300 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.90 |
Taxes
In the past 12 months, DexCom has paid $195.60 million in taxes.
| Income Tax | 195.60M |
| Effective Tax Rate | 26.77% |
Stock Price Statistics
The stock price has decreased by -30.48% in the last 52 weeks. The beta is 1.46, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | -30.48% |
| 50-Day Moving Average | 79.01 |
| 200-Day Moving Average | 76.78 |
| Relative Strength Index (RSI) | 43.15 |
| Average Volume (20 Days) | 2,779,228 |
Short Selling Information
The latest short interest is 10.41 million, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 10.41M |
| Short Previous Month | 11.28M |
| Short % of Shares Out | 2.66% |
| Short % of Float | 2.67% |
| Short Ratio (days to cover) | 2.57 |
Income Statement
In the last 12 months, DexCom had revenue of $4.15 billion and earned $535.20 million in profits. Earnings per share was $1.33.
| Revenue | 4.15B |
| Gross Profit | 2.47B |
| Operating Income | 632.60M |
| Pretax Income | 806.90M |
| Net Income | 535.20M |
| EBITDA | 857.80M |
| EBIT | 632.60M |
| Earnings Per Share (EPS) | $1.33 |
Balance Sheet
The company has $2.70 billion in cash and $2.58 billion in debt, giving a net cash position of $118.20 million or $0.30 per share.
| Cash & Cash Equivalents | 2.70B |
| Total Debt | 2.58B |
| Net Cash | 118.20M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 5.78 |
| Working Capital | 1.52B |
Cash Flow
In the last 12 months, operating cash flow was $964.10 million and capital expenditures -$388.90 million, giving a free cash flow of $575.20 million.
| Operating Cash Flow | 964.10M |
| Capital Expenditures | -388.90M |
| Free Cash Flow | 575.20M |
| FCF Per Share | $1.47 |
Margins
Gross margin is 59.43%, with operating and profit margins of 15.25% and 12.90%.
| Gross Margin | 59.43% |
| Operating Margin | 15.25% |
| Pretax Margin | 17.62% |
| Profit Margin | 12.90% |
| EBITDA Margin | 20.68% |
| EBIT Margin | 15.25% |
| FCF Margin | 13.87% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.45% |
| Shareholder Yield | 3.45% |
| Earnings Yield | 1.68% |
| FCF Yield | 1.81% |
Analyst Forecast
The average price target for DexCom is $98.50, which is 21.59% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $98.50 |
| Price Target Difference | 21.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (5Y) | 14.41% |
| EPS Growth Forecast (5Y) | 26.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 6.35 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.35 |
| Piotroski F-Score | 5 |